Clinical trial
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
NCT00183937
Study timeline
Study start (actual)2005-04-30Date precision: day
Registry last updated2026-05-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
PS 341DRUG
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
University of Southern Californialead sponsor
Millennium Pharmaceuticals, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00183937 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.